These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 8223839)

  • 21. Beta-adrenoceptor blockade and exercise. An update.
    Van Baak MA
    Sports Med; 1988 Apr; 5(4):209-25. PubMed ID: 2897710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations.
    Abrahamsson B; Lücker P; Olofsson B; Regårdh CG; Sandberg A; Wieselgren I; Bergstrand R
    J Clin Pharmacol; 1990 Feb; 30(S2):S46-54. PubMed ID: 1968913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.
    Haria M; Plosker GL; Markham A
    Drugs; 2000 Jan; 59(1):141-57. PubMed ID: 10718104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article.
    Sandberg A; Abrahamsson B; Regårdh CG; Wieselgren I; Bergstrand R
    J Clin Pharmacol; 1990 Feb; 30(S2):S2-16. PubMed ID: 2179280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-release metoprolol succinate in chronic heart failure.
    Tangeman HJ; Patterson JH
    Ann Pharmacother; 2003 May; 37(5):701-10. PubMed ID: 12708950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydrochlorothiazide.
    IARC Monogr Eval Carcinog Risks Hum; 1990; 50():293-305. PubMed ID: 2292804
    [No Abstract]   [Full Text] [Related]  

  • 27. The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers.
    Lundborg P; Abrahamsson B; Wieselgren I; Walter M
    Eur J Clin Pharmacol; 1993; 45(2):161-3. PubMed ID: 8223839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.
    Plosker GL; Clissold SP
    Drugs; 1992 Mar; 43(3):382-414. PubMed ID: 1374320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metoprolol succinate extended release/hydrochlorothiazide combination tablets.
    Hainer JW; Sugg J
    Vasc Health Risk Manag; 2007; 3(3):279-88. PubMed ID: 17703635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.
    Kendall MJ; Maxwell SR; Sandberg A; Westergren G
    Clin Pharmacokinet; 1991 Nov; 21(5):319-30. PubMed ID: 1773547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metoprolol succinate combination in the treatment of hypertension.
    Papadopoulos DP; Papademetriou V
    Angiology; 2009; 60(5):608-13. PubMed ID: 19033265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metoprolol-controlled release, zero order kinetics.
    Kendall MJ
    J Clin Pharm Ther; 1989 Jun; 14(3):159-79. PubMed ID: 2668307
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.